Clinical trials
Lung Cancer (Locally Advanced or Metastatic) clinical trials
Below are recruiting lung cancer (locally advanced or metastatic) clinical trials, each written for real people, not researchers. We’re tracking 5,798 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06821503RecruitingPhase 1/Phase 2
Study of LM-108 with chemo for advanced pancreatic cancer
This trial tests a new drug called LM-108 combined with chemotherapy for people with advanced pancreatic cancer that hasn't been treated before. The goal is to see if it's safe and may help shrink tumors or stop them from growing.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06807359RecruitingPhase 1/Phase 2
Light-activated therapy for localized prostate cancer
This trial uses a special light-activated drug (photodynamic therapy) to treat prostate cancer that is still confined to the prostate. It aims to destroy the cancer while sparing healthy tissue, and may be an option for people with intermediate-risk prostate cancer who have not had other treatments.
New York, New YorkAges 18 years+ - NCT06810609RecruitingPhase 2
Immunochemotherapy, surgery, and durvalumab for stage III lung cancer
This trial tests a combination of immunotherapy, chemotherapy, and either surgery or radiation for people with stage IIIA or IIIB non-small cell lung cancer. The goal is to see if adding the drug durvalumab after standard treatment helps control the cancer better.
Freiburg im Breisgau, Baden-WurttembergAges 18–74 - NCT06329973RecruitingPhase 1/Phase 2
Fruquintinib, sintilimab, and chemo for stomach cancer
This trial tests a combination of three drugs (fruquintinib, sintilimab, and CAPEOX chemotherapy) as a first treatment for advanced stomach or gastroesophageal cancer. The goal is to see if this combination helps slow or shrink the tumor.
Zhengzhou, HenanAges 18–75 - NCT06785636RecruitingPhase 1/Phase 2
New drug combination for advanced prostate cancer
This study tests a new drug (pocenbrodib) alone or combined with another hormone therapy (darolutamide) for men with advanced prostate cancer that has spread. It is for those who have already tried Pluvicto and one other hormone therapy, but not yet chemotherapy.
Fountain Valley, CaliforniaAges 18 years+ - NCT06790693RecruitingPhase 3
Inavolisib plus hormone therapy for advanced breast cancer
This trial tests a new targeted therapy, inavolisib, combined with standard hormone therapy and a CDK4/6 inhibitor for people with a specific genetic mutation (PIK3CA) in their hormone receptor-positive, HER2-negative advanced breast cancer that has not been treated before. It compares this combination to a placebo plus the same standard treatments.
Goodyear, ArizonaAges 18 years+ - NCT06792695RecruitingPhase 2
Study of new treatments for colorectal cancer
This trial tests new treatment combinations for colorectal cancer that has spread (metastatic). It is for people whose cancer is mismatch repair proficient (pMMR) or microsatellite stable (MSS) and who have not had previous treatment for metastatic disease.
Scottsdale, ArizonaAges 18–130 - NCT06778382RecruitingPhase 2
Delaying treatment after destroying lung spots from colorectal cancer
This trial tests if it's safe to wait before starting full-body therapy after treating a small number of lung tumors (5 or fewer) in people whose colorectal cancer had been gone for at least 6 months. You would first get local treatments like surgery or radiation to destroy the lung spots, then delay additional cancer drugs to see how you do.
Jinan, ShandongAges 18–75 - NCT05181033RecruitingPhase 2
Lenvatinib plus letrozole versus fulvestrant for metastatic breast cancer
This Phase 2 study compares a combination medicine (lenvatinib plus letrozole) against fulvestrant to treat metastatic estrogen-receptor positive, HER2-negative breast cancer after the cancer has grown despite hormone therapy plus a CDK4/6 inhibitor. It may help by finding a more effective treatment option after your first lines have stopped working.
SingaporeAges 18–99 - NCT06769152RecruitingPhase 2
HLX43 for advanced gynecological cancers
This trial tests a new drug, HLX43, that targets a protein called PD-L1 found on some cancer cells. It is for people with advanced cervical or ovarian cancer that has stopped responding to standard treatments.
Ji'nan, ShandongAges 18–75 - NCT06768307RecruitingPhase 2
Adebrelimab + Chemo with Radiation for Extensive-Stage SCLC
This study tests whether giving a combination of the immunotherapy drug Adebrelimab plus chemotherapy together with radiation (given at the same time) is better than giving radiation after chemo for people with extensive-stage small cell lung cancer who haven't been treated before.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06710158RecruitingPhase 1
SC-102 for advanced solid tumors
This trial tests a new drug called SC-102 in people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if SC-102 is safe and how well it works.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06757634RecruitingPhase 3
A study of gedatolisib for first-line advanced breast cancer
This trial tests a new targeted therapy called gedatolisib for people with HR-positive, HER2-negative advanced breast cancer who have not yet received treatment for metastatic disease. It aims to see if adding this drug to standard hormone therapy can help control the cancer longer.
Jonesboro, ArkansasAges 18 years+ - NCT06755515Enrolling by invitationPhase 2/Phase 3
Rulonilimab + Chemo for Advanced Cervical Cancer
This trial tests a new drug called Rulonilimab combined with chemotherapy, with or without bevacizumab, as the first treatment for cervical cancer that has spread or come back. It’s for people whose tumors have a specific marker (PD-L1) and who haven’t had other treatments for advanced disease.
Linyi, ShandongAges 18 years+ - NCT06543056RecruitingPhase 2
ES014 for advanced solid tumors
This study tests a new drug called ES014 for people with advanced solid tumors that can't be removed or have spread. It's an early trial to see if ES014 is safe and helps fight certain cancers.
BeijingAges 18 years+ - NCT06747845RecruitingPhase 2
Maintenance therapy for stable metastatic pancreatic cancer
This trial tests a combination of two drugs, niraparib and ipilimumab, as a maintenance treatment for people with metastatic pancreatic cancer that has not grown after initial chemotherapy. The goal is to see if this can help keep the cancer stable longer.
Boston, MassachusettsAges 18 years+ - NCT06745882RecruitingPhase 2
Pembrolizumab for Black Patients with Advanced Lung Cancer
This study tests if the drug pembrolizumab (Keytruda), alone or with chemotherapy, works well for Black patients with advanced non-small cell lung cancer (NSCLC) who haven't had treatment yet. The goal is to see real-world results in this group.
Tampa, FloridaAges 18 years+ - NCT06736275RecruitingEarly Phase 1
Testing a new gene therapy for advanced solid tumors
This trial tests an experimental gene therapy called SXRN for people with advanced solid tumors that haven't responded to standard treatments. The study aims to see if it's safe and may help slow the disease.
BeijingAges 18–75 - NCT06732323RecruitingPhase 3
Study of ESG401 for triple-negative breast cancer that has spread
This trial tests a new drug, ESG401, for people with triple-negative breast cancer that has come back or spread and cannot be removed by surgery. It compares ESG401 to standard chemotherapy options to see which works better.
BeijingAges 18 years+ - NCT06733038RecruitingPhase 3
Chemo plus Avastin with or without Tecentriq for advanced colorectal cancer
This trial tests whether adding the immunotherapy drug atezolizumab (Tecentriq) to standard chemotherapy (FOLFOXIRI) and bevacizumab (Avastin) is more effective as a first treatment for people with a specific type of metastatic colorectal cancer that has a high immune score and is mismatch repair proficient.
Brescia, BSAges 18–75 - NCT06732336RecruitingPhase 1/Phase 2
PET scan for HER2-low breast cancer
This trial uses a special PET scan to see if your breast cancer has low levels of a protein called HER2. This could help doctors choose the right treatment for you.
Sherbrooke, QuebecAges 18 years+ - NCT06727227Recruiting
Study of Enhertu for HER2-low breast cancer
This study looks at how well the drug Enhertu works for patients with HER2-low breast cancer that has spread. If you are already planning to start Enhertu, researchers will collect data from your regular care to learn more about its effectiveness.
Panagyurishte, PazardzhikAges 18 years+ - NCT06716294Recruiting
Radiofrequency ablation and stabilization for spine tumors
This trial tests a treatment that uses heat to destroy active spine tumors from cancer that has spread, followed by stabilizing the bone. It aims to see if the treatment works by using a special scan (PET-CT) to confirm the results.
Athens, AthensAges 18–90 - NCT06249321RecruitingPhase 2
Chemo plus radiation for advanced pancreatic cancer with normal CA19-9
This trial tests a combination of chemotherapy (mFOLFIRINOX) and radiation therapy for people with advanced pancreatic cancer that has stopped responding to chemotherapy and whose CA19-9 tumor marker levels are normal. The goal is to see if this approach can help when standard treatments are no longer working.
Shanghai, Shanghai MunicipalityAges 18–80
Hear when a new Lung Cancer (Locally Advanced or Metastatic) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lung cancer (locally advanced or metastatic)?
- Yes. Clin2 currently lists 5,798 recruiting lung cancer (locally advanced or metastatic) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lung cancer (locally advanced or metastatic) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lung cancer (locally advanced or metastatic) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Locally Advanced or Metastatic Breast Cancer
- Locally Advanced Non-Small Cell Lung Cancer
- Advanced or Metastatic Non-small Cell Lung Cancer
- Colorectal Cancer (Locally Advanced or Metastatic)
- Liver Cancer (Locally Advanced or Metastatic)
- NSCLC (Advanced Non-small Cell Lung Cancer)
- Non Small Cell Lung Cancer Metastatic
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.